ReviewPharmaceutical research2025
Critical Needs and Opportunities for Advanced Manufacturing of Lyophilized Injectables.
Review in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Spray Freeze Drying for Solid Formulations of RNA Lipid Nanoparticles.AAPS PharmSciTech · 2026Article
- Admixture Compatibility Studies in Parenteral Formulations: Packaging, Device, and Regulatory Perspectives.AAPS PharmSciTech · 2026Review
- A Safe and Multifunctional γ-PGA Hydrogel Platform: Endotoxin-Controlled Injectable Fillers and Antimicrobial Wound Dressings.Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lyophilized drugs and biologics have an outsized role in protecting public health due to their ability to provide extended shelf life for stockpiling. Over 70% (14 out of 19) of antibiotics on the Essential Medicines list are supplied as lyophilized sterile powders for injection (FDA, 1). Additionally, many new drugs, including first-in-kind medicines, such as the first checkpoint inhibitor cancer immunotherapy Keytruda, were initially introduced to market in a lyophilized form, accelerating availability to patients by several years while a stable liquid formulation was being developed. The article describes methodologies, both short-term and long-term, to address the current manufacturing challenges for lyophilized injectables based on the findings of the workshop by National Institute of Pharmaceutical Technology and Education held in January 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.